Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Differential induction of T-cell tolerance by tumour fibroblast subsets
Curr Opin Immunol. 2024 Jan 17;86:102410. doi: 10.1016/j.coi.2023.102410. Online ahead of print.ABSTRACTT-cell immunotherapy is now a first-line cancer treatment for metastatic melanoma and some lung cancer subtypes, which is a welcome clinical success. However, the response rates observed in these diseases are not yet replicated across other prominent solid tumour types, particularly stromal-rich subtypes with a complex microenvironment that suppresses infiltrating T cells. Cancer-associated fibroblasts (CAFs) are one of the most abundant and pro-pathogenic players in the tumour microenvironment, promoting tumour neogenes...
Source: Current Opinion in Immunology - January 18, 2024 Category: Allergy & Immunology Authors: Zoe Mx Chua Fitsumbhran Tajebe Mohammed Abuwarwar Anne L Fletcher Source Type: research
Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment
Curr Opin Immunol. 2023 Dec 27;86:102409. doi: 10.1016/j.coi.2023.102409. Online ahead of print.ABSTRACTTumour necrosis factor (TNF) is a primary mediator of inflammatory processes by facilitating cell death, immune cell activation and triggering of inflammation. In the cancer context, research has revealed TNF as a multifaceted cytokine that can be both pro- or anti-tumorigenic depending on what context is observed. We explore the plethora of ways that TNF and its receptors manipulate the functional and phenotypic characteristics in the tumour microenvironment (TME) on both tumour cells and immune cells, promoting either ...
Source: Current Opinion in Immunology - December 28, 2023 Category: Allergy & Immunology Authors: Louisa F Alim Colm Keane Fernando Souza-Fonseca-Guimaraes Source Type: research
Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment
Curr Opin Immunol. 2023 Dec 27;86:102409. doi: 10.1016/j.coi.2023.102409. Online ahead of print.ABSTRACTTumour necrosis factor (TNF) is a primary mediator of inflammatory processes by facilitating cell death, immune cell activation and triggering of inflammation. In the cancer context, research has revealed TNF as a multifaceted cytokine that can be both pro- or anti-tumorigenic depending on what context is observed. We explore the plethora of ways that TNF and its receptors manipulate the functional and phenotypic characteristics in the tumour microenvironment (TME) on both tumour cells and immune cells, promoting either ...
Source: Current Opinion in Immunology - December 28, 2023 Category: Allergy & Immunology Authors: Louisa F Alim Colm Keane Fernando Souza-Fonseca-Guimaraes Source Type: research
Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment
Curr Opin Immunol. 2023 Dec 27;86:102409. doi: 10.1016/j.coi.2023.102409. Online ahead of print.ABSTRACTTumour necrosis factor (TNF) is a primary mediator of inflammatory processes by facilitating cell death, immune cell activation and triggering of inflammation. In the cancer context, research has revealed TNF as a multifaceted cytokine that can be both pro- or anti-tumorigenic depending on what context is observed. We explore the plethora of ways that TNF and its receptors manipulate the functional and phenotypic characteristics in the tumour microenvironment (TME) on both tumour cells and immune cells, promoting either ...
Source: Current Opinion in Immunology - December 28, 2023 Category: Allergy & Immunology Authors: Louisa F Alim Colm Keane Fernando Souza-Fonseca-Guimaraes Source Type: research
